• Q3A - Q3D Impurities

    Code Document Title Previously coded
    • Finalised Guideline:
      June 2006

      Description :

      This Guideline has been first revised and finalised under Step 4 in February 2003. It complements the Guideline on impurities in new drug substances and provides advice in regard to impurities in products containing new, chemically synthesized drug substances. The Guideline specifically deals with those impurities which might arise as degradation products of the drug substance or arising from interactions between drug substance and excipients or components of primary packaging materials. The Guideline sets out a rationale for the reporting, identification and qualification of such impurities based on a scientific appraisal of likely and actual impurities observed, and of the safety implications, following the principles elaborated in the parent Guideline. Threshold values for reporting and control of impurities are proposed, based on the maximum daily dose of the drug substance administered in the product.

      The Attachment 2 of this Guideline has been revised under Step 4 without further public consultation on 2 June 2006 (Q3B(R2)).

      Implementation :

      Step 5


      EC, EuropeAdopted by CPMP, June 2006, issued as CPMP/ICH/2738/99


      MHLW/PMDA, Japan Adopted 3 July 2006, PFSB/ELD Notification No. 0703004


      FDA, US Published in the Federal Register, 14 November 2003, Vol, 68, No. 220, p. 64628-9 with the Revised Attachment 2


      Health Canada, Canada Implemented 15 June 2015, File #: 15-106634-508


      Swissmedic, Switzerland - Refer to the press release on Swissmedic, Switzerland's website